Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Sclerosis
100%
Patient Benefit
100%
Patient Selection
100%
Patient Risk
100%
Natalizumab
100%
JC Virus
100%
Multiple Sclerosis Treatment
50%
Virus-neutralizing Antibody
50%
Immunosuppression
33%
Progressive multifocal Leukoencephalopathy
33%
Disease-modifying Therapy
16%
Highly Effective
16%
Aggressive Disease
16%
Disease Course
16%
Risk Stratification
16%
Decision-making Process
16%
Prior Exposure
16%
Accuracy Analysis
16%
First-line Therapy
16%
Antibody-negative
16%
Low Positive
16%
Line Positions
16%
Medicine and Dentistry
Multiple Sclerosis
100%
Patient Selection
100%
JC Virus
100%
Natalizumab
100%
Virus Antibody
50%
Immunosuppressive Treatment
33%
Progressive Multifocal Leukoencephalopathy
33%
Decision Making
16%
Clinician
16%
Disease Modifying Therapy
16%
Disease Course
16%
Risk Stratification
16%
Neuroscience
Multiple Sclerosis
100%
Natalizumab
100%
JC Virus
100%
Virus Antibody
50%
Immunosuppression
33%
Progressive Multifocal Leukoencephalopathy
33%
Decision-Making Process
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Natalizumab
100%
JC Virus
100%
Virus Antibody
50%
Progressive Multifocal Leukoencephalopathy
33%
Disease Course
16%
Diseases
16%